Essential Thrombocythemia Clinical Trial
Official title:
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: - The safety and tolerability of Bomedemstat - The pharmacodynamic effect of Bomedemstat
This is a Phase 2 multi-center, open-label study evaluating the safety, efficacy and pharmacodynamics of Bomedemstat administered orally once daily in patients with essential thrombocythemia (ET). Patients will be dosed with Bomedemstat for 169 consecutive days in the Initial Treatment Period (ITP). Qualifying patients may continue to receive Bomedemstat in the Additional Treatment Period (ATP). Safety will be evaluated by clinical assessments of safety parameters i.e., safety laboratory testing, adverse event reporting, physical examination and vital sign assessments. Pharmacodynamics will be evaluated by hematology assessment, patient reported symptom burden, change in spleen size by palpation and other measures. To ensure safety, a Safety Advisory Board will perform periodic reviews of safety parameters and pharmacodynamic markers. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05482971 -
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
|
Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
Completed |
NCT00666549 -
Research Tissue Bank
|
||
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01192347 -
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
|
||
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Recruiting |
NCT04942080 -
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
|
N/A | |
Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Active, not recruiting |
NCT04262141 -
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
|
Phase 2 | |
Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
Active, not recruiting |
NCT00588991 -
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
|
Phase 1 | |
Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
Completed |
NCT01787552 -
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03116542 -
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
|
N/A | |
Recruiting |
NCT06361641 -
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
|
N/A | |
Recruiting |
NCT06378437 -
A Study of GLB-001 in Patients With Myeloid Malignancies
|
Phase 1 | |
Recruiting |
NCT05882773 -
Asian Myeloproliferative Neoplasm (MPN) Registry
|
||
Completed |
NCT02129101 -
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
|
Phase 1 | |
Completed |
NCT00357305 -
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
|
Phase 1 |